Neurotoxicity due to accumulation of aluminium (AI) in uremic patients is demonstrated by: a} the appearance of a specific syndrome, dialysis dementia (DO), unmistakably related to the duration and amount of exposure to the metal; b) the correlation between the metal concentration in tissue and the appearance of histopathological alterations possibly related to neurotoxicity, namely neurofibrillary degeneration and neurocellular disorders; c) the regression of symptoms when the patient is no longer exposed to AI, or when measures are taken to remove the metal from the organism; d) the fact that uremic populations not exposed to intoxication never show symptoms could be attributed to AI neurotoxicity.
Although the main source of intoxication is dialysate with high concentrations of AI from domestic tap water treated with AI(OHh as a flocculant, other ways in which the metal can be introduced into the organism include chronic oral administration of intestinal phosphorous chelating agents containing AI(OHh or contaminated venous infusion and, in uremic children, AI contamination from milk formulas.
Whereas there is an evident cause/effect relationship (obvious source of intoxication, high AI concentrations in serum and tissue, neurological symptoms) in DO, which is considered an acute form of intoxication, chronic intoxication from AI(OHh is more insidious. It can give rise to sporadic cases of DO, but above all it is a concomitant cause of cerebral atrophy. From this point of view, a retrospective study of the possible causes of cerebral atrophy in patients undergoing long-term hemodialysis indicated chronic intake of AI(OHh as one of the most significantly correlated factors (1) and probably an additional or aggravating factor in peripheral neuropathy through damage to the mechanisms of axonal transport. This article describes possible mechanisms of aluminium neurotoxicity on the basis of clinical and experimental data.
Facilitated intestinal AI absorption in uremic patients
In renal disease AI accumulation in tissues and its consequent toxicity is mainly due to poor elimination, since the metal is normally excreted by the kidney, and to higher-than-normal intestinal absorption, facilitated by the concomitant administration of vitamin 0 and probably also by a tendency, masked or overt, to chronic hyperparathyroidism (hPTH) (2) with related alteration of the bivalent ions.
Two epidemiological observations at first sight far removed from the subject appear to back up the hypothesis that hPTH may facilitate the absorption of AI. The incidence of amyotrophic lateral sclerosis and degenerative Parkinson's disease (ALS/PO) among inhabitants of the island of Guam and other Western Pacific areas is fifty times higher than in Europe (3). The water and soil of the islands are exceptionally rich in AI and poor in Ca and Mg. Accumulation of AI in specific brain areas was observed in patients suffering from the diseases. In Britain too, in certain towns where the local water is rich in AI, the incidence of Alzheimer's disease is much higher than in the rest of the country (4). The AI concentration in nerve cells with neurofibrillary degeneration is higher than normal.
Although the ALS/PO syndromes of the Guam islanders have also been attributed to an unusual non-protein aminoacid from the false sago palm (5) , and although there is no definite connection between Alzheimer's disease and AI (the presence of AI in neurons containing neurofibrillary tangles is sometimes considered a secondary etiological toxic agent), the possibility remains that in uremic patients ionic alterations involving Ca and Mg associated with hPTH facilitate the passage of AI into the gastrointestinal tract.
AI, neurofibrillary degeneration (NO) and impaired axonal transport
ND is a non-specific but unequivocal expression of neuronal distress, seen in a variety of neurological conditions such as Alzheimer's disease, pugilistic encephalopathy, Guamonian Parkinson dementia, etc. In all these wide-flung disorders the neuronal damage is clear from various cellular alterations, including the reduced size of the nucleoles, and a high AI concentration in brain tissues is a common denominator.
ND has been seen in the cortical neurons of patients who died of DD (6) . This indicates the importance of the relationship between AI neurotoxicity and ND in AI intoxicated uremic patients and in fact ND can be induced in animals by AI salts: lower tissue concentrations are needed to induce ND in cats, rabbits and guinea pigs than in rats and rhesus monkeys (7). Resistance to AI intoxications in ND therefore varies from species to species. The same picture has been observed in cultured human neurons (8) .
Impaired axonal transport
Leaving aside the different specialization of the two systems, damage to the central nervous system (CNS) and the peripheral nervous systems (PNS) can be caused to AI interfering with axonal transport.
There are three components of axonal transport: a) anterograde slow axonal transport (SC) which can in turn be divided into two slow components, SCa consisting of a microtubule and neurofilament network, and SCb consisting of microfilaments with their complexed proteins, including actin; b) anterograde fast axonal transport consisting of vesicles and smooth endoplasmic reticulum, and c) retrograde fast axonal transport consisting of secondary Iysosomes and multivesicular bodies. AI intoxication chiefly impairs anterograde slow axonal transport.
The events resulting from SC impairment can be studied in a model of experimental intoxication with I3I3-iminodipropionitrile which damages axonal flow in a way very similar to AI (9) . Perikaryal protein synthesis continues, and with it, the formation of neurofilaments, but the impaired anterograde slow axonal transport makes it difficult for them to move along the axon. They therefore accumulate in the proximal sections of the axon in total disorganization and segregation, leading eventually to ND. AI damage of this sort is seen in rabbits intoxicated with AICI 3 (10) .
An excess of AI in the cytoskeleton and particularly in the neurotubules can interfere with the dynamic balance between the polymerized state of alpha and beta tubulin -the proteins making up the neurotubules -thus impeding the polymerization phase, as demonstrated in vitro and in vivo (11) . Damage to the neurotubules, which can be visualized as the "fast lines" along which axonal transport runs, has negative repercussions on the flow of cell organelles, resulting in disorganization. AI intoxication, however, also impedes physiological disassembly of the cytoskeleton which gives rise to retrograde axonal transport (12) . This damage is associated with distal axonopathies typically linked to the signs and symptoms of symmetrical "dying back neuropathy", one of which is uremic polyneuropathy.
The cytoskeletal damage is accompanied by modifications in calmodulin (see below), which is one of the components of the microfilaments.
Even though the pathogenic sequences are not known in detail, it is clear that AI intoxication of nerve tissue has the power to damage the entire axonal transport system.
Damage by AI to nerve tissue energy metabolism
The explanation of how AI intoxication interferes with the energy metabolism of nerve tissue by inhibiting its main source of energy, glucose, is both chemico-physical and biochemical. Firstly, the ion radius of 0.51A enables AI to replace Mg (radius 0.66A) in the MgATP complex, with the formation of a more stable AI-ATP complex, and secondly, the AI-ATP complex then blocks hexokinase (13), needed to catalyse the conversion of glucose to G6P, the only complex which can be used by the cerebral carbohydrate energy metabolism.
The sensitivity of cerebral hexokinase is shown by the very low concentrations of the AI needed to block it (even lower than those found in normal brain tissue) (14) and recent kinetic studies have demonstrated that the AI-ATP complex is a competitive inhibitor of ATP and a non-competitive inhibitor of glucose (14, 15) . However, in the Krebs cycle the lack of Mg means that isocitrate is not changed to ketoglutarate by isocitrate dehydrogenase.
The importance of the energy metabolism for nerve functions is illustrated by demential pathologies in which the carbohydrate metabolism is altered and by the fact that even very small alterations of utilization have negative repercussions on the neurotransmitter metabolism and on acetylcholine in particular (16) .
Functional and structural damage to the
The phosphorylation of specific substrate proteins involved in nerve excitability and in interneuronal transmission -by means of the regulation of ion flows in membrane channels -and in neurotransmitter biosynthesis is dependent on the action of catalyzing proteins. One of these, calmodulin (ClM), interacts with the substrate after its conformation has been modified through interaction with the ion Ca One of ClM's basic functions in relation to the cells is to activate membrane ATPase, the pump which expels Ca 2 + from the cell and, given its affinity with Ca 2 +, to act directly as a buffer. Thermodynamic analysis shows that the affinity between AI and ClM is ten times the physiological affinity between Ca 2 + and ClM (17); electron paramagnetic resonance spectroscopy and calorimetry also indicate that the AIClM bonds are more stable in the first of these complexes, probably on account of the highly solvated nature of AI, which generates coordinated covalent bonds that modify the polypeptide regions within the structure of ClM. Since ClM regulates intracellular biochemical processes in which Ca 2 + is the second messenger, the intracellular concentration of Ca 2 + must remain stable at least four orders of magnitude lower than the extracellular concentration, as the membrane gradient essential for the integrity of the cell is allowed by the expulsion of excess intracellular Ca 2 +. Without ClM modulation, uncontrolled intracellular reactions may take place. Excess Ca 2 + may combine with phosphates of ATP, turning them into insoluble salts and thus making them unavailable for energy pu rposes (18) .
In experimental AI intoxication, this physico-chemical activity is accompanied by a steady increase of Ca 2 + in the nerve tissue and although cerebral ClM remains stable, its activity is reduced, providing in vivo proof of the in vitro observation that AI denatures ClM thus lowering its activity without any quantitative reduction (19) . In various human encephalopathies, including uremia, Alzheimer's disease and Guamonian dementia, an increase in the amount of AI in cells is accompanied by a corresponding increase in Ca
Neurotransmitter modifications induced by an excess of AI in tissues
Uremia involves numerous abnormalities in the brain content of cholinergic and adrenergic neurotransmitters and of gamma-amino butyric acid (GA-BA). In patients with DO, choline actyltransferase (ChAT) activity in the cerebral cortex is reduced, as it is in patients with no neurological signs of 00 undergoing chronic hemodialysis treatment -in this case ChAT is reduced by 23-30% (20) . It can thus be concluded that reduced ChAT activity co-exists with high concentrations of AI in the brain tissue.
In non-uremic conditions, experimental observations indicate the pathogenic role of AI intoxication in cerebral neurotransmitter mechanisms. ChAT activity in cultures of neuroblastoma cells is inhibited when AI is added (21) . AI intoxication in rabbits causes a drop in ChAT activity together with the appearance of encephalopathy (22) . In laboratory animals, administration of AI in the ventricular system reduces the concentration of acetylcholine in brain tissue. In synaptosome fractions in vitro the introduction of AI inhibits choline uptake, just as it inhibits choline transport in isolated rat brain nerve endings (28). When the AI content rises in NO-affected cells, various measures of presynaptic cholinergic nerve function are reduced, including choline uptake, acetylcholine synthesis and ChAT activity.
In dialyzed patients with 00 symptoms or with brain tissue AI intoxication the concentration of GABA, a nerve transmission inhibitor widely found throughout the CNS, is reduced by about 40% in the thalamus and the cortex; this does not occur in uremic patients, dialyzed and non-dialyzed, not suffering from AI intoxication. The experimental model in which AI inhibits the uptake of synaptosomal GABA confirms that the presence of AI reduces GABA synthesis.
More difficult to fit into the picture are data regarding adrenergic neurotransmitters. In uremia, catecholamine levels are magnified by reduced clearance, by reduced reuptake and by a catechol-omethyltransferase deficit, so that cerebral levels of norepinephrine metabolites in hemodialyzed patients are only apparently normal. In the brain tissue of decreased uremic patients, serotonin (the precursor) levels are high and dopamine (the neurotransmitter) low. In uremic rats cerebral levels of dopamine, norepinephrine and epinephrine are reduced. In the non-uremic experimental model -synaptosomal fractions from rat brain -AI showed a selective inhibitory effect on the uptake of dopamine, norepinephrine and serotonin (24) .
The synthesis of adrenergic transmitters passes through a co-factor, tetrahydrobiopterin (BH)4, derived from dihydroneopterin in the presence of Mg ions. Again, AI appears to act through ionic displacement and interference of Mg.
If there is no BH 4 synthesis, normal quantitative synthesis of adrenergic transmitters cannot take place. Although its interpretation is open to debate, the excess of AI must have a negative influence on BH 4 metabolism since conditions other than uremia in which there is cerebral accumulation of AI are accompanied by a lack first of BH 4 then of adrenergic transmitter synthesis: examples are the senescent brain, Alzheimer's disease, type II and type III hyperphenylalaninemia, AI-intoxicated cells in vitro.
The activity of dihydropterin reductase (DHPR), the enzyme essential for BH 4 regeneration, is reduced by 40% in the preparation of cerebral extracts when AI salts are added in concentrations comparable to those in brain tissue of uremic patients suffering from DO (25) .
Erythrocytes, which seem to possess DHPR activity comparable to that of the nerve tissue, have enabled us to confirm that enzymatic activity is inversely correlated to the serum concentrations of AI and that this correlation can be extended to nerve tissues. Treatment with deferroxamine, which chelates AI, restores normal DHPR activity.
Therefore AI intoxication causes varying degrees of damage to neurotransmitter synthesis, on which neurocellular function and trophism depend.
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CONCLUSIONS
Aluminium neurotoxicity is a iatrogenic pathology that is frequent and asymptomatic in uremic patients in general and dialyzed patients in particular. It can, however, lead to important symptoms and even death.
Wide-ranging biochemical, animal, toxicological, physico-chemical and clinical studies have shown that AI accumulation in tissue induces histopathological and functional alterations. Measures to limit the use of compounds containing AI in the uremic patient are therefore mandatory. Unfortunately, despite widespread agreement on this point, they are often only partially put into practice.
